Global ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Executive Summary
The most prevalent neuro developmental disorder in children is attention deficit hyperactivity disorder (ADHD). It frequently persists into adulthood and is typically diagnosed for the first time in childhood. Children with ADHD may struggle to pay attention, lose or forget things, daydream frequently, act without considering the consequences, or be overactive. Both non-stimulant and stimulant medications are used to treat ADHD.
Market Size and Key Findings
The Global ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market size is at around US $ Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.
Global ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Size (In USD Bn)
(2021-2030F)
Market Dynamics
Market Growth Drivers Analysis
Due to the lack of a cure for this disorder, the prevalence of ADHD is increasing at a faster rate, which drives the global market for therapeutics for the condition. Additionally, the market for ADHD therapeutics is primarily driven by the negative effects of unstable lifestyles and food additives on children, which is increasing the prevalence of ADHD in people between the ages of 4 to 17. Additionally, it is predicted that in the near future, the Global market for ADHD will experience revenue growth due to rising awareness of the syndrome among doctors and patients as well as opinion-based treatment options caused by the absence of routine diagnostic tests.
Market Restraints
The development of the global market for ADHD therapeutics is being constrained by the high cost of ADHD medications, poor reimbursement policies, and side effects associated with ADHD medications (such as insomnia, anorexia, dizziness, headaches, and mood changes). The adverse effects of ADHD medications also have a negative impact on patient's quality of life and restrain the market's revenue growth over the course of the given forecast period. Aside from these issues, medications for attention deficit hyperactivity disorder are linked to medical conditions like kidney disease, coronary artery disease, and seizures.
Competitive Landscape
Key Players
The prominent players operating in this market include Pfizer (US), Eli Lily & Company (US), Johnson & Johnson Services, LLC (US), Lupin (India), Prude Pharma L.P. (US), Shire (US), Mallinckrodt (UK) and NEOS Therapeutics Inc (US)
TABLE OF CONTENT
1. Report Description of the Global ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market
